4D Molecular Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
4D Molecular Therapeutics, Inc. (FDMT) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of 2.40% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2024-02-29
- 4D Molecular Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 2.40%, a 84.62% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 1.30%, a 38.10% decline from fiscal 2021.
- 4D Molecular Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 2.10%, a 25.00% decline from fiscal 2020.
- 4D Molecular Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2020 was 2.80%, a 46.15% decline from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2023-12-31 | 2.40% 10-K · filed 2024-02-29 | |
| 2022-12-31 | 1.30% 10-K · filed 2024-02-29 | 1.50% 10-K · filed 2023-03-15 |
| 2021-12-31 | 2.10% 10-K · filed 2023-03-15 | |
| 2020-12-31 | 2.80% 10-K · filed 2022-03-28 | |
| 2019-12-31 | 5.20% 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |